Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis
Recruiting · NCT04592640 · Interventional (participants receive a specific treatment) · Lead sponsor: The First Affiliated Hospital with Nanjing Medical University
View the official record on ClinicalTrials.gov →Interventions studied
Human amniotic-derived mesenchymal stem cells
What this trial is about
Treatment for Calciphylaxis Patients with Human Amniotic-derived Mesenchymal Stem Cells
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Early Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- 18-75 years old.
- Clinical diagnosis of calciphylaxis, including patients with chronic kidney disease who did not or had regular dialysis (hemodialysis or peritoneal dialysis).
- All subjects signed informed consent.
Exclusion criteria
- Patients who refuse to sign informed consent.
- Patients with malignant tumors or severe psychiatric disorders, or an expected survival time of less than 6 months.
- Pregnant or lactating women of childbearing age.
- Participation in another clinical trial with an experimental drug within 90 days prior the inclusion.
Where it is running
1 location listed.
- The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital - Nanjing, Jiangsu, China